SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Aethlon Medical,
Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted
therapeutic devices to address infectious disease and cancer,
announced today that the Aethlon Hemopurifier® has been named one
of the 25 best inventions of 2014 by Time Magazine. The
article can be found on-line at the following link:
http://time.com/3594971/the-25-best-inventions-of-2014
The Aethlon Hemopurifier® is a first-in-class bio-filtration
device that targets the rapid elimination of viruses and
immunosuppressive proteins from the circulatory system of infected
individuals. To date, the device has been utilized in the
treatment of Ebola, HIV and Hepatitis C virus. Time previously
reported on the successful use of Hemopurifier® therapy in an Ebola
patient with multiple organ failure. The article can be found
on-line at the following link:
http://time.com/3586271/ebola-treatment-dialysis-blood
About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address
infectious disease, cancer and neurodegenerative
disorders. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively
targets the rapid elimination of circulating viruses and
tumor-secreted exosomes that promote cancer progression. Exosome
Sciences, Inc. is a majority owned subsidiary that is advancing
exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. For more information,
please visit http://www.aethlonmedical.com/ and connect with the
Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the ESI will not be
able to commercialize its future products, that the FDA will not
approve the initiation of the Company's clinical programs or
provide market clearance of the company's products, future human
studies whether revenue or non-revenue generating of the Aethlon
ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C
therapies or as a standalone cancer or hepatitis C therapy or as a
broad spectrum defense against viral pathogens, including ebola,
the Company's ability to raise capital when needed, the Company's
ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or
through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the
milestones contemplated in the DARPA contract, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Leah-Michelle Nebbia (for
interviews requests)
Golin
202-585-2651
lnebbia@golin.com
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Logo -
http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b
SOURCE Aethlon Medical, Inc.